Loading organizations...
Based in Mason, Ohio, Assurex Health is a precision medicine and pharmacogenomics company founded in 2006 by James Burns, Craig Keizur, John Kelsoe, and David Mrazek. The organization's flagship GeneSight test analyzes patient DNA to help healthcare providers select optimal psychotropic drugs for behavioral health and chronic pain conditions, reaching over two million patients. The firm's core technology was originally licensed from the Mayo Clinic and Cincinnati Children's Hospital Medical Center, attracting early venture backing from Sequoia Capital and Claremont Creek Ventures. Prior to its acquisition, the successful enterprise generated over $60 million in annual revenue and employed a dedicated staff of more than 450 people. In August 2016, the growing company was acquired by Myriad Genetics for $225 million upfront and up to $185 million in performance milestones to integrate into its neuroscience division.
Assurerx Health has raised $148.3M across 9 funding rounds.
Assurerx Health has raised $148.3M in total across 9 funding rounds.
Assurerx Health has raised $148.3M across 9 funding rounds. Most recently, it raised $15.0M Series D in December 2015.
Assurerx Health has raised $148.3M in total across 9 funding rounds.
Assurerx Health's investors include Allos Ventures, Cincy Tech, Cincinnati Children, Claremont Creek Ventures, Cross Creek Advisors, Mayo Clinic, Sequoia Capital, American Financial Group, CincyTech, Danmar Capital, Mason, Four Rivers Group.
# Assurex Health: A Personalized Medicine Pioneer
Assurex Health is a personalized medicine company specializing in pharmacogenomics—the study of how genetic factors influence individual responses to medications[2][4]. The company develops and commercializes genetic testing technology to help healthcare providers determine the most appropriate medications and dosages for patients with neuropsychiatric and chronic pain conditions[1][4].
The company's flagship product, GeneSight®, is a lab-developed pharmacogenetic test that combines genetic testing with algorithmic interpretation to guide physicians in prescribing psychiatric medications[1]. Rather than a one-size-fits-all approach to mental health treatment, Assurex Health enables clinicians to make data-driven medication decisions based on each patient's unique genetic profile, ultimately improving treatment outcomes and reducing healthcare costs[4].
Founded in 2006 and based in Mason, Ohio, Assurex Health emerged from a strategic partnership with two world-renowned medical institutions[2][4]. The company licensed patented technology from Cincinnati Children's Hospital Medical Center and Mayo Clinic, both of which continued as research collaborators[2][4]. This institutional backing provided credibility and scientific rigor from inception.
The company received early support from CincyTech (a seed fund), local angel investors, and regional economic development programs including Ohio's JobsOhio initiative[4]. By 2012, Assurex Health had gained sufficient traction to win the Luis Villalobos Award for innovation from the Angel Capital Association, with backing from regional angel groups including Queen City Angels, Ohio Tech Angels, and the North Coast Angel Fund[2].
Assurex Health operates at the intersection of precision medicine and digital health, riding the broader shift toward individualized treatment protocols in healthcare. The company addresses a fundamental challenge in psychiatry: medication selection remains largely trial-and-error, with patients often cycling through multiple drugs before finding effective treatment. By introducing genetic science into this decision-making process, Assurex Health helps reduce treatment delays, improve patient outcomes, and lower overall healthcare expenditures—aligning with healthcare systems' cost-containment priorities.
The company's success reflects growing recognition that pharmacogenomics is clinically and economically valuable, particularly in mental health treatment where medication efficacy varies dramatically between individuals. This positions Assurex Health within the broader personalized medicine ecosystem alongside molecular diagnostics leaders.
In August 2016, Assurex Health was acquired by Myriad Genetics (NASDAQ: MYGN) for $225 million upfront with potential for $185 million in performance-based milestones[2]. The acquisition represented validation of the company's technology and market opportunity, with Assurex Health becoming a wholly-owned subsidiary while maintaining its Mason, Ohio headquarters[4].
Under Myriad's ownership, Assurex Health's GeneSight test continues to expand its clinical footprint in behavioral health and precision psychiatry. As mental health awareness increases and healthcare systems seek evidence-based approaches to reduce medication trial-and-error cycles, pharmacogenomic testing is likely to become increasingly integrated into standard psychiatric care. The company's trajectory reflects how specialized diagnostic technology can create significant value by solving a specific, high-impact clinical problem.
